G

Glenmark Pharmaceuticals Ltd
NSE:GLENMARK

Watchlist Manager
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Watchlist
Price: 1 541.05 INR 1.39% Market Closed
Market Cap: 434.9B INR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

GLENMARK Price Targets Summary
Glenmark Pharmaceuticals Ltd

Wall Street analysts forecast GLENMARK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GLENMARK is 1 703.95 INR with a low forecast of 1 277.65 INR and a high forecast of 2 133.6 INR.

GLENMARK Lowest Forecast
Wall Street Target
1 277.65 INR
17% Downside
GLENMARK Average Forecast
Wall Street Target
1 703.95 INR
11% Upside
GLENMARK Highest Forecast
Wall Street Target
2 133.6 INR
38% Upside
Lowest
Price Target
1 277.65 INR
17% Downside
Average
Price Target
1 703.95 INR
11% Upside
Highest
Price Target
2 133.6 INR
38% Upside
Glenmark Pharmaceuticals Ltd Competitors:
Price Targets
600079
Humanwell Healthcare Group Co Ltd
23% Upside
A
AETHER
Aether Industries Ltd
30% Upside
4151
Kyowa Kirin Co Ltd
32% Upside
AZN
AstraZeneca PLC
26% Upside
600079
Humanwell Healthcare Group Co Ltd
23% Upside
A
AETHER
Aether Industries Ltd
30% Upside
4151
Kyowa Kirin Co Ltd
32% Upside
AZN
AstraZeneca PLC
26% Upside
600195
China Animal Husbandry Industry Co Ltd
27% Upside
ALKEM
Alkem Laboratories Ltd
13% Upside
T
TORNTPHARM
Torrent Pharmaceuticals Ltd
12% Upside
IPCALAB
IPCA Laboratories Ltd
15% Upside

Revenue
Forecast

Revenue Estimate
Glenmark Pharmaceuticals Ltd

For the last 8 years the compound annual growth rate for Glenmark Pharmaceuticals Ltd's revenue is 6%. The projected CAGR for the next 3 years is 13%.

6%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Glenmark Pharmaceuticals Ltd

For the last 8 years the compound annual growth rate for Glenmark Pharmaceuticals Ltd's operating income is -8%. The projected CAGR for the next 3 years is 68%.

-8%
Past Growth
68%
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Glenmark Pharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-15%
Average Miss
What are analyst estimates?

See Also

Summary
GLENMARK intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLENMARK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLENMARK stock valuation using valuation multiples.
Wall Street Estimates
GLENMARK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLENMARK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GLENMARK's stock price target?
Price Target
1 703.95 INR

According to Wall Street analysts, the average 1-year price target for GLENMARK is 1 703.95 INR with a low forecast of 1 277.65 INR and a high forecast of 2 133.6 INR.

What is Glenmark Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
13%

For the last 8 years the compound annual growth rate for Glenmark Pharmaceuticals Ltd's revenue is 6%. The projected CAGR for the next 3 years is 13%.

What is Glenmark Pharmaceuticals Ltd's Operating Income forecast?
Projected CAGR
68%

For the last 8 years the compound annual growth rate for Glenmark Pharmaceuticals Ltd's operating income is -8%. The projected CAGR for the next 3 years is 68%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 242,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.